Authors' recommendations: Data from randomised controlled trials of the hypomethylating agents (azacitidine and decitabine) indicate that, for the first time, the natural history of MDS may be changed by non-intensive therapy with an acceptable toxicity profile. Recent trials have shown a survival benefit in patients treated with these agents when compared to patients treated with supportive or conventional care. High risk older patients, with low performance status and co-morbid disease who are not eligible for high dose/intensive therapeutic options currently form the bulk of the patient population treated with hypomethylating agents. There have also been randomised controlled trials to establish the most effective dose schedule. However, morphologic evidence of disease rarely disappears with treatment and several courses may be needed for best response. Clinical trials of combination therapy incorporating hypomethylating agents are ongoing.

Project Status: Completed

URL for project: http://www.healthsac.net/downloads/publications/HSAC25_Hypomethylating_Agents_150410_FINAL.pdf

Year Published: 2010

URL for published report: n/a

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: New Zealand

Organisation Name: Health Services Assessment Collaboration

Contact Address: University of Canterbury, Private Bag 4800, Christchurch 8140, New Zealand

Contact Name: hsac@canterbury.ac.nz

Contact Email: hsac@canterbury.ac.nz

Copyright: <p>Health Services Assessment Collaboration (HSAC)</p>